Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Bio X Cell Announces Board of Director Appointments

This image opens in the lightbox

News provided by

Bio X Cell

17 Oct, 2024, 06:00 GMT

Share this article

Share toX

Share this article

Share toX

A Leading Producer of Monoclonal Antibodies

LEBANON, N.H., Oct. 17, 2024 /PRNewswire/ -- Bio X Cell, LLC ("BXC" or the "Company"), the world's leading producer of monoclonal antibodies for pre-clinical in vivo research applications, is pleased to announce the appointments of Alan Hirzel and Kevin Ballinger to its Board of Directors.

"We are thrilled to welcome Alan Hirzel to the board alongside Kevin Ballinger, who joined earlier this year," said Chris Conway, CEO of Bio X Cell. "Alan and Kevin bring a wealth of experience and industry knowledge to the table, which will serve us well as we execute on BXC's extraordinary strategic growth opportunities following the Company's recent acquisition by Windjammer Capital Investors."

"Alan's deep domain expertise in the antibody space, and success building out the Abcam platform as its former CEO, will prove invaluable as we scale the Bio X Cell business," said Craig Majernik, Managing Director at Windjammer. "He's a terrific complement to Kevin who, as the former CEO of Aldevron, led that business through a period of significant growth, and during a period of transition from founder to private equity ownership and, ultimately, to a strategic acquirer."

"Many of the same value creation levers we were able to capitalize on at Aldevron, I see at Bio X Cell," said Kevin Ballinger. "It is rare to find a business so well positioned for growth. We've assembled a very capable leadership team to pair with the Company's strong core group of employees. Together they are pursuing best practices that will no doubt lead to success in realizing those opportunities."

"Bio X Cell is at an exciting inflection point," said Alan Hirzel. "Knowing the industry and understanding how disciplined execution of a well-defined strategy can contribute to outsized growth, I'm confident in being able to contribute to the value creation process. This was an important consideration in joining the board, so I'm delighted to be partnering with the BXC and Windjammer teams."  

About Alan Hirzel

Mr. Hirzel is an accomplished business leader, investor and former CEO of Abcam, where he led a decade-long transformation that significantly enhanced the company's business model, innovation, brand and operational quality, culminating in its acquisition by Danaher for $5.7 billion in December 2023. During his tenure at Abcam, he led the company to provide highly validated antibodies for use in early detection and stratification of patients prescribed antibody drugs in oncology. Prior to Abcam, Mr. Hirzel was a Partner at Bain & Company in London, where he led the Healthcare Practice and advised executives and private equity investors on growth strategies. He holds a B.S. in Plant Molecular Biology, M.S. in Bioprocessing and MBA from Cornell University.

About Kevin Ballinger

Mr. Ballinger is an accomplished, results-driven executive, board member and, from 2020 to 2023, was CEO of Aldevron, a leading manufacturer of nucleic acids and proteins used for gene and cell therapies, gene editing technologies, DNA and RNA vaccines. He was recruited to scale the organization, increase capabilities and commercial footprint, and remained in place following Danaher's $9.6 billion acquisition of the company in 2021. Prior to Aldevron he spent 25 years at Boston Scientific, most recently as EVP and Global President of Interventional Cardiology. He holds a B.S. in Mechanical Engineering from Michigan Technological University and MBA from the University of Minnesota.

About Bio X Cell

Bio X Cell is the world's leading producer of high purity monoclonal antibodies (mAbs) primarily for use in preclinical in vivo research applications. The Company's 450+ functional grade antibodies are used by 1,500+ academic, government, pharmaceutical, and biotech customers in a wide range of research areas including oncology, immunology, neuroscience and infectious disease, as reflected in more than 20,000 research publication citations. BXC is headquartered in the US with distribution centers in Germany, China, Singapore and Korea, and partnerships with over 30 global distributors, enabling supply of mAbs to customers in over 50 countries throughout the world.

To learn more visit https://bioxcell.com/

Media Contact:
Connor Halverson
That's Nice LLC, on behalf of Bio X Cell
Tel: +1 212 366 4455
Email: connor@thatsnice.com

Logo - https://mma.prnewswire.com/media/2479584/BioXcell_Logo.jpg

Modal title

Also from this source

Bio X Cell Expands Global Reach with New Distribution Center in Beijing, China

Bio X Cell Expands Global Reach with New Distribution Center in Beijing, China

Bio X Cell, the world's leading provider of functional antibodies for translational research, is strengthening its global distribution network with...

Bio X Cell Announces CEO Appointment

Bio X Cell Announces CEO Appointment

Bio X Cell, LLC ("BXC" or the "Company"), a leading producer of monoclonal antibodies for pre-clinical in vivo research applications, is pleased to...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Biotechnology

Biotechnology

Clinical Trials & Medical Discoveries

Clinical Trials & Medical Discoveries

Personnel Announcements

Personnel Announcements

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.